Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...

The FDA did not request additional clinical or non-clinical data US regulators have refused to file Bristol Myers Squibb and bluebird bio’s marketing application seeking approval of idecabtagene ...

Drugmaker Bristol-Myers Squibb and a biotech company with which it has partnered have sent their application to the Food and Drug Administration seeking approval for what could become the first ...

Pfizer and Bristol-Myers Squibb are erecting a wall of patent infringement lawsuits that they hope will slow the advance of generic versions of their shared blockbuster Eliquis. The partners this week ...

Two companies looking to market a CAR-T cell therapy for multiple myeloma encountered a delay as the Food and Drug Administration highlighted documentation issues in their regulatory application ...